Artesunate

N/A

Artesunate, an artemisinin derivative, is a powerful antimalarial drug. It is used for both adults and children. It is indicated for the following conditions: Treatment of severe and complicated malaria caused by Plasmodium falciparum both in adults and in children in areas where there is multidrug resistance. ... Read moreArtesunate, an artemisinin derivative, is a powerful antimalarial drug. It is used for both adults and children. It is indicated for the following conditions: Treatment of severe and complicated malaria caused by Plasmodium falciparum both in adults and in children in areas where there is multidrug resistance. Treatment of uncomplicated malaria in situations where there is the widespread prevalence of multidrug-resistant Plasmodium falciparum. Artesunate tablet is also suitable to salvage patients with pernicious malaria and treat malaria caused by Plasmodium falciparum and Plasmodium vivax.

N/A

Artesunate is contraindicated for patients with known hypersensitivity to Artemisinin and its derivatives or its inactive ingredients.

Artesunate is metabolized to the active DHA. the endoperoxide bridge of DHA reacts with heme, generating free radicals which inhibit protein and nucleic acid synthesis of the Plasmodium parasites during all erythrocytic stages. Reactions with these free radicals can also lead to alkylation of parasitic proteins such as a calcium adenosine triphosphatase and EXP1, a glutathione S-transferase.

Artesunate may have interaction with other artemisinin drugs i.e. artemether, arteether which have the same effect in prolonging the PQ and QT interval. It has interaction when it is given with other antimalarial drugs (eg. Quinine, quinidine, mafloquine and halofantrine) which have cardiac action. It also has interaction with other drugs which prolong QT interval (such as erythromycin, terfenadine, astemizole, probucol, procainamide, disopyramide, amiodarone, bretylium, bepridil, sotalol, tricyclic antidepressants and neuroleptics).

Artesunate tablet is well tolerated. No adverse effects have been reported from the treatment of artesunate at recommended dose.

A WHO report assessing the safety of artemisinin derivatives in pregnancy concluded that these drugs should continue to be available for the treatment of malaria in pregnancy, irrespective of the trimester. WHO also stressed that further study was needed. Therefore Artesunate tablet should be given to pregnant women especially, in first trimester if recommended by Registered Physician. Like many other drugs there is possibility for presence of artesunate in breast milk. Because of potential of adverse effect of artesunate in nursing baby, breast-feeding should be stopped during the treatment of malaria by Artesunate tablet.

This tablet should be used with caution in patients vomiting severely. For emergency treatment of patients suffering from severe malaria, intravenous or intramuscular injection is preferred. Do not use the drug without the advice of a Registered Physician. Do not exceed the recommended dose.